Show simple item record

dc.contributor.authorAbella Cajigal, Vanesa
dc.contributor.authorScotece, Morena
dc.contributor.authorConde Aranda, Javier
dc.contributor.authorLópez López, Verónica
dc.contributor.authorLazzaro, Veronica
dc.contributor.authorPino Mínguez, Jesús 
dc.contributor.authorGómez-Reino Carnota, Juan Jesús 
dc.contributor.authorGualillo ., Oreste 
dc.date.accessioned2017-06-07T07:25:48Z
dc.date.available2017-06-07T07:25:48Z
dc.date.issued2014
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/20.500.11940/6333
dc.description.abstractThe metabolic syndrome (MetS) is a cluster of cardiometabolic disorders that result from the increasing prevalence of obesity. The major components of MetS include insulin resistance, central obesity, dyslipidemia, and hypertension. MetS identifies the central obesity with increased risk for cardiovascular diseases (CVDs) and type-2 diabetes mellitus (T2DM). Patients with rheumatic diseases, such as rheumatoid arthritis, osteoarthritis, systemic lupus erythematosus, and ankylosing spondylitis, have increased prevalence of CVDs. Moreover, CVD risk is increased when obesity is present in these patients. However, traditional cardiovascular risk factors do not completely explain the enhanced cardiovascular risk in this population. Thus, MetS and the altered secretion patterns of proinflammatory adipokines present in obesity could be the link between CVDs and rheumatic diseases. Furthermore, adipokines have been linked to the pathogenesis of MetS and its comorbidities through their effects on vascular function and inflammation. In the present paper, we review recent evidence of the role played by adipokines in the modulation of MetS in the general population, and in patients with rheumatic diseases.
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdipokines 
dc.subject.meshAdiponectin 
dc.subject.meshMetabolic Syndrome
dc.subject.meshRheumatic Diseases 
dc.titleAdipokines, metabolic syndrome and rheumatic diseases
dc.typeArtigoes
dc.authorsophosAbella, V.
dc.authorsophosScotece, M.
dc.authorsophosConde, J.
dc.authorsophosLopez, V.
dc.authorsophosLazzaro, V.
dc.authorsophosPino, J.
dc.authorsophosGomez-Reino, J. J.
dc.authorsophosGualillo, O.
dc.identifier.doihttp://dx.doi.org/10.1155/2014/343746
dc.identifier.sophos16574
dc.issue.number343746
dc.journal.titlePLoS One
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago::IDIS.- Instituto de investigaciones sanitarias de Santiago
dc.page.initial343746
dc.rights.accessRightsopenAccess
dc.subject.decsAdipoquinas
dc.subject.decsAdiponectina 
dc.subject.decsSíndrome Metabólico
dc.subject.decsEnfermedades Reumáticas
dc.typesophosArtículo de Revisión
dc.volume.number2014


Files in this item

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
Except where otherwise noted, this item's license is described as Atribución 4.0 Internacional